Alumis Inc. (ALMS)
| Market Cap | 2.81B +869.9% |
| Revenue (ttm) | 8.40M -51.7% |
| Net Income | -237.42M |
| EPS | -2.31 |
| Shares Out | 127.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 567,311 |
| Open | 22.25 |
| Previous Close | 22.02 |
| Day's Range | 21.73 - 22.72 |
| 52-Week Range | 2.76 - 30.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 40.10 (+82.11%) |
| Earnings Date | May 14, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price target is $40.1, which is an increase of 82.11% from the latest price.
News
Alumis price target raised to $40 from $38 at Chardan
Chardan raised the firm’s price target on Alumis (ALMS) to $40 from $38 and keeps a Buy rating on the shares, reflecting updated pricing assumptions for envudeucitinib, modest changes in…
Alumis Proxy statement: Proxy filing
Alumis filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Alumis Proxy statement: Proxy filing
Alumis filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Alumis price target raised to $39 from $38 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Alumis (ALMS) to $39 from $38 and keeps an Overweight rating on the shares.
Alumis price target raised to $51 from $49 at Wells Fargo
Wells Fargo raised the firm’s price target on Alumis (ALMS) to $51 from $49 and keeps an Overweight rating on the shares. The firm believes the Street-implied probability of success…
Alumis Slides: Corporate presentation
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Alumis price target raised to $34 from $32 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Alumis (ALMS) to $34 from $32 and keeps a Buy rating on the shares. The firm’s raised target reflects the…
Alumis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Alumis (ALMS) to Neutral from Buy with an unchanged price target of $25. The firm cites valuation for the downgrade. The current share price…
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
Reports Q1 revenue $1.74M, consensus $2.49M. As of March 31, Alumis (ALMS) had cash, cash equivalents and marketable securities of $569.5M. “Alumis delivered a focused and productive first quarter, bu...
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and r...
Alumis Earnings release: Q1 2026
Alumis released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Alumis Quarterly report: Q1 2026
Alumis has published its Q1 2026 quarterly earnings report on May 14, 2026.
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
Raymond James keeps a Strong Buy rating on Alumis (ALMS) following what appears to be a major success at AAD, where Phase 3 data showed envudeucitinib delivering efficacy broadly comparable…
Alumis price target raised to $55 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on Alumis to $55 from $50 and keeps an Outperform rating on the shares. The firm sees the three new orals for psoriasis –…
Alumis price target lowered to $25 from $40 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Alumis (ALMS) to $25 from $40 and keeps a Buy rating on the shares. The firm says the oral…
Alumis Transcript: Study update
Envudeucitinib’s phase III ONWARD trials showed robust skin clearance, rapid itch reduction, and strong quality-of-life improvements in moderate to severe plaque psoriasis, with a favorable safety profile through 24 weeks. Its efficacy, especially in itch relief, positions it as a leading oral option, with further studies planned.
Alumis Press release: Study update
Alumis issued a press release on March 29, 2026, disclosing material business information to investors.
Alumis Slides: Study update
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on March 29, 2026.
Alumis announces data from Phase 3 Onward1, Onward23 trials of envudeucitinib
Alumis (ALMS) announced new data from its Phase 3 Onward1 and Onward2 clinical trials evaluating envudeucitinib, a next-generation, highly selective oral tyrosine kinase 2 inhibitor for moderate-to-se...
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
Alumis price target raised to $38 from $33 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Alumis (ALMS) to $38 from $33 and keeps an Overweight rating on the shares. Q4 EPS was “a non-event,”…
Alumis files automatic mixed securities shelf
17:04 EDT Alumis (ALMS) files automatic mixed securities shelf
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
– Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psori...
Alumis Annual report: Q4 2025
Alumis has published its Q4 2025 annual report on March 19, 2026.